Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Norfolk Southern Corporation (NSC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Norfolk Southern Corporation — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $284.59 (market cap $39.89B), while Norfolk Southern Corporation trades at $326.93 (market cap $73.55B). The key difference: Norfolk Southern Corporation is the larger of the two by market cap, and Norfolk Southern Corporation pays a 1.65% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | NSC | |
|---|---|---|
Market Cap | $39.89B | $73.55B |
Sector | Health | Technology |
52-Week High | $491.22 | $327.47 |
52-Week Low | $278.09 | $259.49 |
Enterprise Value | $38.15B | $89.31B |
Dividend Yield | — | 1.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Norfolk Southern (NSC) trades at $327.47, up 1.14% with a bullish technical outlook and strong fundamental performance. The stock shows consistent earnings beats, with Q1 2026 EPS of $2.65 exceeding expectations of $2.49. Valuation metrics include a P/E of 27.59 and ROE of 17.6%, while analyst consensus targets $342.67. Recent developments include the pending merger with Union Pacific and upcoming Q2 2026 earnings on July 23, 2026.
NSC presents a favorable investment case with strong profitability and merger potential, though regulatory scrutiny and rich valuations pose risks. The stock's proximity to 52-week highs suggests limited near-term upside, but long-term growth prospects remain solid if merger approvals proceed smoothly and operational efficiency improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Norfolk Southern Corporation
Norfolk Southern Corporation is a major North American railroad company operating one of the largest freight rail networks in the eastern United States. The company transports a diverse range of commodities, including coal, intermodal containers, and various industrial products. NSC is a critical link in the nation's supply chain, providing efficient, long-haul transportation services to and from ports and industrial centers.
Read more on NSC →
